Document 0352
 DOCN  M9460352
 TI    [Cancer of the kidney: changes in blood lymphocyte subsets induced by
       treatment with interferon alpha-2b and interleukin-2r]
 DT    9408
 AU    Raymond E; Boaziz C; Komarover H; Breau JL; Moliard M; Morere JF; Israel
       L; Clinique d'oncologie medicale, Hopital Avicenne, Bobigny,; France.
 SO    Bull Cancer (Paris). 1993 Apr;80(4):299-309. Unique Identifier :
       AIDSLINE MED/94227368
 AB    Twenty patients (6 females and 14 males), age range 36-70 years-old,
       with metastatic renal cell carcinoma (MRCC), received interferon
       alpha-2b (IFN-A) 10 x 10(6) units/day IM for 5 days followed by
       continuous i.v. infusion of interleukin-2 (IL-2) 18 x 10(6) units/day
       for 5 days. The median follow-up was 10 months. We observed four partial
       responses (20%), 13 stable (65%) and three progressive diseases (15%).
       The mean CD4/CD8 ratio, obtained before therapy in patients with MRCC,
       was compared with CD4/CD8 ratio in 51 patients with different advanced
       malignancy and in patients with no cancer. The CD4/CD8 ratio was higher
       in patients with MRCC (2.55) than in other cancers (1.474) and than in
       populations with no cancer (1.66 x chi 2 = 17,378). The surface
       phenotypes of peripheral lymphocytes were analysed by cytofluorometry in
       patients with MRCC during and after treatment with IFN-A and IL-2.
       Immune modulatory effects of therapy immediately induced a decrease of
       different sub-populations of lymphocytes except CD25+. Far from the
       first course, a rise in lymphocyte count was observed. The proliferation
       effect was as follows: CD4+, CD8+, CD4+ CD45RA- and CD16+ CD8- cells.
       Far from the second and 3rd course, the sub-populations of lymphocytes
       decreased, except the CD4+ and CD4- CD45RA+ cells. The CD4/CD8 ratio
       increased progressively during treatment. Before each course, the
       CD4/CD8 ratio of patients with response to treatment was higher than the
       CD4/CD8 ratio of patients with no response. Results were non-significant
       due to the small number of subjects with responses in this study.
 DE    Adult  Aged  B-Lymphocyte Subsets/*DRUG EFFECTS  CD4-CD8 Ratio  English
       Abstract  Female  Human  Interferon Alfa-2b/PHARMACOLOGY/*THERAPEUTIC
       USE  Interleukin-2/PHARMACOLOGY/*THERAPEUTIC USE  Kidney
       Neoplasms/BLOOD/*THERAPY  Male  Middle Age  Neoplasm Metastasis
       Treatment Outcome  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).